Companies · Pharmaceuticals

VBI Vaccines Inc/BC

CAMBRIDGE · Pharmaceuticals

Diligence memoA one-page analyst read on VBI Vaccines Inc/BC — recommendation, valuation, rhythm, risks.
$41.6M
Total raised · real
7
Rounds
4.4×
Latest step-up
Top 22%
Sector rank · raised
Series A
Latest stage · inferred · Fri May 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

VBI Vaccines Inc/BC looks fair against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.95× the median modeled value of Series A Pharmaceuticals companies in 2019–2021 (76 peers) — value vs value, same stage and era.
  • Within the normal band (95% of peer median) for its niche.
Dormant
  • Last raise 6.1 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

VBI Vaccines Inc/BC is one of 1613 Pharmaceuticals companies tracked from CAMBRIDGE. By capital raised it ranks in the upper tier (ahead of 79% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2020-05-22
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MPre-Seed · 2010-08-31 Raised $275K (real) Modeled valuation $13M (est)Pre-Seed2010Series A · 2014-10-21 Raised $4.4M (real) Modeled valuation $136M (est)Series A2014Series A · 2016-06-20 Raised $14M (real) Modeled valuation $422M (est)Series A2016Series A · 2016-12-06 Raised $11M (real) Modeled valuation $328M (est)Series A2016Series A · 2018-12-04 Raised $7.0M (real) Modeled valuation $217M (est)Series A2018Series A · 2020-04-24 Raised $1.1M (real) Modeled valuation $33M (est)Series A2020Series A · 2020-05-22 Raised $4.7M (real) Modeled valuation $146M (est)Series A2020+$4.4M+$14M+$11M+$7.0M+$1.1M+$4.7MCumulative $42M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$275K · 2010
Series A$4.4M · 2014no Seed on file
Series A extension$13.6M · 2016
Series A extension$10.6M · 2016
Series A extension$7.0M · 2018
Series A extension$1.1M · 2020
Series A extension$4.7M · 2020

Stages are modeled from round size (public records carry no series label). No record for: Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$145.6M
Base estimate est.
$5.4M
Conservative case
$791.5M
Upside case
$21.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $13.0M · 2010-08-312010Series A · modeled $136.3M · 2014-10-21Series A · modeled $421.5M · 2016-06-20Series A · modeled $328.3M · 2016-12-06Series A · modeled $216.8M · 2018-12-04Series A · modeled $32.8M · 2020-04-24Series A · modeled $145.6M · 2020-05-222020
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
6.0 yr
Elapsed time used
6.1 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
19 mo
Avg between rounds
$4.3M/yr
Capital velocity
15.8 yr
On record since
2010
First round
7
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 5.1× above median
This company$41.6M
Sector median$8.1M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.9× of median
This company$4.7M
Sector median$5.2M
Modeled value — vs sector median (estimate, all stages) 1.9× above median
This company$145.6M
Sector median$76.1M

Raised more than 79% of sector peers (real $). Modeled value above 62% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #42 of 76.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)Xynomic Pharmaceuticals Holdings, Inc. · Series A Raised $15.0M · modeled $464.6M (est)Honest Globe Inc. · Series A Raised $15.0M · modeled $464.6M (est)Athenen Therapeutics, Inc. · Series A Raised $12.0M · modeled $371.7M (est)Zomedica Pharmaceuticals Corp. · Series A Raised $25.6M · modeled $371.7M (est)CerSci Therapeutics Inc. · Series A Raised $12.0M · modeled $371.7M (est)Rational Vaccines, Inc. · Series A Raised $27.8M · modeled $363.5M (est)Primmune Therapeutics, Inc. · Series A Raised $20.1M · modeled $350.3M (est)Aytu Bioscience, Inc · Series A Raised $28.8M · modeled $309.7M (est)Solaris Pharma Corp · Series A Raised $23.4M · modeled $309.7M (est)Ally Therapeutics, Inc. · Series A Raised $10.0M · modeled $309.7M (est)Avitide, Inc. · Series A Raised $40.9M · modeled $309.7M (est)PharmAbbie, Inc. · Series A Raised $15.0M · modeled $282.0M (est)VBI Vaccines Inc/BC (this company) Raised $41.6M · modeled $145.6M (est)VBI Vaccines Inc/BC
CompanyStageRaised · realValue · estvs peer med.
Xynomic Pharmaceuticals Holdings, Inc.Series A$15.0M$464.6M3.05×
Honest Globe Inc.Series A$15.0M$464.6M3.05×
Athenen Therapeutics, Inc.Series A$12.0M$371.7M2.44×
Zomedica Pharmaceuticals Corp.Series A$25.6M$371.7M2.44×
CerSci Therapeutics Inc.Series A$12.0M$371.7M2.44×
Rational Vaccines, Inc.Series A$27.8M$363.5M2.38×
Primmune Therapeutics, Inc.Series A$20.1M$350.3M2.30×
Aytu Bioscience, IncSeries A$28.8M$309.7M2.03×
Solaris Pharma CorpSeries A$23.4M$309.7M2.03×
Ally Therapeutics, Inc.Series A$10.0M$309.7M2.03×
Avitide, Inc.Series A$40.9M$309.7M2.03×
PharmAbbie, Inc.Series A$15.0M$282.0M1.85×
VBI Vaccines Inc/BC this companySeries A$41.6M$145.6M0.95×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$275K2010-08-31$1.5M$13.0M85%
Series A$4.4M2014-10-21$20.0M$136.3M85%
Series A$13.6M2016-06-20$61.9M$421.5M85%
Series A$10.6M2016-12-06$48.2M$328.3M90%
Series A$7.0M2018-12-04$31.8M$216.8M90%
Series A$1.1M2020-04-24$4.8M$32.8M90%
Series A$4.7M2020-05-22$21.4M$145.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$275K2010-08-31
    • First recorded raise — entered as Pre-Seed.
    • 14 investors on this round.
  2. Series A$4.4M2014-10-21
    • Raised again after 50 mo — slower than the ~13 mo sector norm.
    • Round 16.0× larger than the prior — scaling up.
    • Switched to Rule 506(c) (was Rule 06).
    • 11 investors on this round.
  3. Series A$13.6M2016-06-20
    • Raised again after 20 mo — slower than the ~13 mo sector norm.
    • Round 3.1× larger than the prior — scaling up.
    • Switched to Rule 506(b) (was Rule 506(c)).
    • 3 investors on this round.
  4. Series A$10.6M2016-12-06
    • Came back fast: 6 mo vs the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • 2 investors on this round.
  5. Series A$7.0M2018-12-04
    • Raised again after 24 mo — slower than the ~13 mo sector norm.
    • Round 1.5× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  6. Series A$1.1M2020-04-24
    • Raised 17 mo later, in step with the ~13 mo sector norm.
    • Round 6.6× smaller than the prior — bridge or down round.
    • 61 investors on this round.
  7. Series A$4.7M2020-05-22
    • Came back fast: 1 mo vs the ~13 mo sector norm.
    • Round 4.4× larger than the prior — scaling up.
    • 1 investor on this round.
Intelligence
2022 ~Q1
Modeled next raise · ~19mo cadence
$14.1M
Modeled next size est.range $9.2M$22.6M
4.4×
Last step-up
$4.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Steven Gillis22 other2016-06
David Anderson20 other2016-06
Steve Gillis12 other2018-12
James Martin8 other2016-06
Steven Rubin6 other2016-06
Scott Requadt4 other2016-06
Jeff Baxter3 other2016-06
David E. Anderson2 other2018-12
Egidio Nascimento2 other2016-12
FRANCISCO DIAZ-MITOMA2 other2020-04
Tomer Kariv2 other2018-12
ADAM LOGAL1 other2016-06
Blaine McKee1 other2020-04
David C. Wolfin1 other2010-08
Gary C. Robertson1 other2010-08
SAM CHAWLA1 other2016-06
William C. Glasier1 other2010-08
Annie H. Chan2014-10
Athena E. Kartsaklis2018-12
Avi E. Mazaltov2018-12
Avi Mazaltov2020-04
Carlos H. Fernandez-Mazzi2014-10
Christopher E. McNulty2018-12
Christopher McNulty2020-04
Registry & provenance

VBI Vaccines Inc/BC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
764195
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Variation Biotechnologies (US), Inc.BiotechnologySeries A$17.1M$54.2Mnetwork5 shared operators · same stage
Vbi Vaccines Inc.BiotechnologySeries B$53.6M$249.5Mnetwork3 shared operators
Cocrystal Pharma, Inc.PharmaceuticalsSeries A$28.9M$92.9Mnetwork1 shared operator · same sector · same stage
Plx Pharma Inc.PharmaceuticalsSeries A$26.6M$40.2Mnetwork1 shared operator · same sector · same stage
Ally Therapeutics, Inc.PharmaceuticalsSeries A$10.0M$309.7Mnetwork1 shared operator · same sector · same stage
ESSA Pharma Inc.PharmaceuticalsSeries B$56.0M$1.2Bnetwork1 shared operator · same sector
Pulmatrix, Inc.PharmaceuticalsSeries B$62.9M$86.2Mnetwork1 shared operator · same sector
Bralorne Gold Mines Ltd.OtherPre-Seed$778K$18.0Mnetwork3 shared operators
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Vaccinex, Inc.PharmaceuticalsSeries A$936K80%
VQ Biomedical, Inc.BiotechnologySeed$7.6M78%
vTv Therapeutics Inc.PharmaceuticalsSeries C$502.3M77%
VST BIO CorpPharmaceuticalsSeries B$118.7M76%
Rational Vaccines, Inc.PharmaceuticalsSeries A$363.5M75%
Virocell Biologics LtdBiotechnologyPre-Seed$12.9M75%
DBV Technologies S.A.PharmaceuticalsSeries D+$2.6B75%
Bpv-1 LlcPharmaceuticalsSeed$76.1M75%
Frequently asked
How much funding has VBI Vaccines Inc/BC raised?
VBI Vaccines Inc/BC has raised approximately $41.6M in disclosed capital across 7 recorded financing rounds, aggregated from public filings.
What is VBI Vaccines Inc/BC's estimated valuation?
Provath's modeled valuation for VBI Vaccines Inc/BC is approximately $145.6M (modeled range $5.4M–$791.5M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is VBI Vaccines Inc/BC at?
VBI Vaccines Inc/BC's latest modeled financing stage is Series A. Its most recent recorded round closed around Fri May 22.
What does VBI Vaccines Inc/BC do and where is it based?
VBI Vaccines Inc/BC operates in the Pharmaceuticals sector, based in CAMBRIDGE.
Explore related

See where VBI Vaccines Inc/BC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at VBI Vaccines Inc/BC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.